Skip to main content

Oligoprogressive clinical trials at UCLA

1 research study open to eligible people

Showing trials for
  • PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

    open to eligible people ages 18 years and up

    Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.

    Los Angeles, California and other locations

Our lead scientists for Oligoprogressive research studies include .

Last updated: